Potential new weapon to fight cancer

Researchers have discovered a new weapon that looks set to play a pivotal role in the battle against various cancers and inflammatory diseases.

A team at QIMR Berghofer says that an important immune system protein has the potential to treat a wide range of cancers and inflammatory diseases once harnessed through immunotherapy.

The researchers explained they had been working on the tropical parasitic diseases malaria and leishmaniasis when they discovered that the natural killer cell granule protein (NKG7) played an important role in a range of diseases, including melanoma, where a large immune response from the body was required.

Professor Christian Engwerda, the acting head of QIMR Berghofer’s infectious diseases program, said his team found that when the NKG7 protein was turned off, it reduced inflammation in mice, but if it was stimulated, it enhanced the immune response.

“NKG7 is a key promoter of inflammation, which is the basis of many of the diseases we encounter, including cancers, autoimmune diseases, neurological diseases and infectious diseases,” he said.

He explained that the protein had been identified decades ago, but that no-one had worked out it was a key weapon of the immune system and vitally important in controlling tumours and infections and helping medicines to work well.

“It does this by delivering the toxic agents from immune cells to targeted disease cells,” he said. “Our research shows that in cancer, the protein is activated when patients are treated with drugs that switch on the immune system to deliver cancer-killing agents to tumours.

“In autoimmune and other inflammatory diseases where the immune system is overactive, the NKG7 protein is too active, and we found by blocking it in mice, inflammatory damage was reduced.”

The research was conducted in mice and human blood samples collected from leishmaniasis patients in India. (Leishmaniasis is a parasitic disease found in parts of the tropics, subtropics, and southern Europe.) The researchers found leishmaniasis patients expressed high levels of the molecule in their blood.

Co-lead author, QIMR Berghofer senior scientist and immunology department coordinator Professor Mark Smyth, said the findings opened the way for new immunotherapies.

“NKG7 is expressed on different immune cells at different stages of disease and our study showed that targeting the protein by blocking its function would be a new way to dampen inflammation in diseases,” he said.

“Activating it, on the other hand, would enhance the immune response during some infectious diseases and cancer.

“Our research showed some cancer patients who responded well to certain immunotherapies expressed high levels of this molecule in the immune cells attacking their tumours, indicating it can play a role in preventing cancer metastasis.”

He said the challenge now was to explore what drugs could be used to manipulate the protein in the immune system, so doctors could either turn it on or off, depending on the disease or condition.

Prof. Engwerda said the research demonstrated the value of studying a broad range of diseases, including those that did not directly affect Australians.

“Apart from it being important for us to play our part as global citizens by trying to find cures for diseases impacting the developing world, this study shows research into any illness can expand our understanding of the immune system and the biology of disease,” he said.

The research was led in collaboration with the Institute of Medical Sciences at Banaras Hindu University in Varanasi, India, as part of a long-standing India-Australia relationship.

The study has been published in the journal Nature Immunology.

Have you been treated for cancer the ‘old-fashioned’ way? Do you follow the development of these new immunotherapies?

If you enjoy our content, don’t keep it to yourself. Share our free eNews with your friends and encourage them to sign up.

Related articles:

Janelle Ward
Janelle Wardhttp://www.yourlifechoices.com.au/author/janellewa
Energetic and skilled editor and writer with expert knowledge of retirement, retirement income, superannuation and retirement planning.
- Our Partners -


- Advertisment -
- Advertisment -